Aptorum Group Ltd Class A (APM) - Net Assets
Based on the latest financial reports, Aptorum Group Ltd Class A (APM) has net assets worth $13.79 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.69 Million) and total liabilities ($4.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Aptorum Group Ltd Class A's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.79 Million |
| % of Total Assets | 73.79% |
| Annual Growth Rate | -6.44% |
| 5-Year Change | -21.22% |
| 10-Year Change | N/A |
| Growth Volatility | 68.97 |
Aptorum Group Ltd Class A - Net Assets Trend (2016–2025)
This chart illustrates how Aptorum Group Ltd Class A's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see APM company net worth.
Annual Net Assets for Aptorum Group Ltd Class A (2016–2025)
The table below shows the annual net assets of Aptorum Group Ltd Class A from 2016 to 2025. Also explore APM net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $13.79 Million | +17.11% |
| 2024-12-31 | $11.78 Million | -23.44% |
| 2023-12-31 | $15.38 Million | +96.38% |
| 2022-12-31 | $7.83 Million | -55.25% |
| 2021-12-31 | $17.51 Million | -54.12% |
| 2020-12-31 | $38.15 Million | +156.89% |
| 2019-12-31 | $14.85 Million | -54.65% |
| 2018-12-31 | $32.75 Million | +8.33% |
| 2017-12-31 | $30.23 Million | +20.36% |
| 2016-12-31 | $25.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aptorum Group Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2403.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $80.00 | 0.00% |
| Other Comprehensive Income | $-92.31K | -0.40% |
| Other Components | $97.00 Million | 419.64% |
| Total Equity | $23.12 Million | 100.00% |
Aptorum Group Ltd Class A Competitors by Market Cap
The table below lists competitors of Aptorum Group Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CML Microsystems Plc
LSE:CML
|
$570.77K |
|
IMMUTABLE HOLDINGS INC.
F:B8X0
|
$571.40K |
|
Ireka Corporation Bhd
KLSE:8834
|
$571.89K |
|
MEDICOX Co. Ltd
KQ:054180
|
$573.12K |
|
SDCL EDGE Acquisition Corporation
NYSE:SEDA
|
$570.01K |
|
Ilika plc
LSE:IKA
|
$568.68K |
|
Founder Group Limited Ordinary Shares
NASDAQ:FGL
|
$568.59K |
|
Ecoclime Group AB Series B
ST:ECC-B
|
$567.02K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aptorum Group Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,134,514 to 23,115,160, a change of 1,980,646 (9.4%).
- Net loss of 1,363,270 reduced equity.
- New share issuances of 5,070,000 increased equity.
- Other comprehensive income decreased equity by 181,472.
- Other factors decreased equity by 1,544,612.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.36 Million | -5.9% |
| Share Issuances | $5.07 Million | +21.93% |
| Other Comprehensive Income | $-181.47K | -0.79% |
| Other Changes | $-1.54 Million | -6.68% |
| Total Change | $- | 9.37% |
Book Value vs Market Value Analysis
This analysis compares Aptorum Group Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.26x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.08x to 0.26x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $100.41 | $8.32 | x |
| 2018-12-31 | $118.65 | $8.32 | x |
| 2019-12-31 | $56.40 | $8.32 | x |
| 2020-12-31 | $132.68 | $8.32 | x |
| 2021-12-31 | $67.39 | $8.32 | x |
| 2022-12-31 | $44.02 | $8.32 | x |
| 2023-12-31 | $54.96 | $8.32 | x |
| 2024-12-31 | $38.76 | $8.32 | x |
| 2025-12-31 | $31.44 | $8.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aptorum Group Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.81x
- Recent ROE (-5.90%) is above the historical average (-36.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -8.50% | 0.00% | 0.00x | 1.01x | $-4.65 Million |
| 2017 | -8.42% | 0.00% | 0.00x | 1.04x | $-5.57 Million |
| 2018 | -44.79% | -3868.04% | 0.01x | 1.36x | $-18.14 Million |
| 2019 | -114.22% | -3491.81% | 0.02x | 1.46x | $-20.32 Million |
| 2020 | 16.89% | 775.31% | 0.02x | 1.06x | $2.88 Million |
| 2021 | -106.10% | -1624.38% | 0.07x | 0.93x | $-27.41 Million |
| 2022 | -62.37% | -756.17% | 0.06x | 1.33x | $-11.37 Million |
| 2023 | -11.37% | -654.88% | 0.02x | 0.83x | $-5.31 Million |
| 2024 | -20.19% | 0.00% | 0.00x | 0.76x | $-6.38 Million |
| 2025 | -5.90% | 0.00% | 0.00x | 0.81x | $-3.67 Million |
Industry Comparison
This section compares Aptorum Group Ltd Class A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $201,571,196
- Average return on equity (ROE) among peers: -90.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aptorum Group Ltd Class A (APM) | $13.79 Million | -8.50% | 0.36x | $570.06K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $112.13 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $44.03 Million | -144.75% | 1.47x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.36 Billion |
| Arbutus Biopharma Corp (ABUS) | $76.58 Million | -43.75% | 0.24x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $723.96K | -677.23% | 9.41x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $8.92 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $732.79 Million | 30.90% | 0.62x | $4.75 Billion |
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more